Novartis Acquires Avidity Biosciences – Biotech Deal
- Novartis, the Swiss pharmaceutical giant, has agreed to acquire Avidity Biosciences, a U.S.-based biotechnology company, for approximately $12 billion.
- As part of the agreement, Avidity Biosciences will spin off its early-stage precision cardiology programs into a new, independent company called Spinco.
- the acquisition is expected to close in the first quarter of 2024, subject to the satisfaction of customary closing conditions, including regulatory approvals.
“`html
Novartis to Acquire avidity Biosciences for $12 Billion
Table of Contents
overview
Novartis, the Swiss pharmaceutical giant, has agreed to acquire Avidity Biosciences, a U.S.-based biotechnology company, for approximately $12 billion. The deal, announced on October 26, 2023, values Avidity at $72 per share in cash, representing a 46% premium over its closing price on Friday, October 20, 2023. The acquisition aims to bolster NovartisS drug pipeline and drive future growth.
Deal Details and Spinco
As part of the agreement, Avidity Biosciences will spin off its early-stage precision cardiology programs into a new, independent company called Spinco. This strategic move allows novartis to focus on Avidity’s core strengths while enabling the advancement of the cardiology programs under a separate entity. The financial terms of the Spinco creation were not disclosed in initial reports.
the acquisition is expected to close in the first quarter of 2024, subject to the satisfaction of customary closing conditions, including regulatory approvals. Novartis intends to finance the acquisition wiht existing cash reserves.
Strategic Rationale
Novartis has been actively seeking acquisitions to strengthen its drug pipeline and accelerate growth. The company is notably interested in innovative therapies in areas with high unmet medical needs. Avidity Biosciences’s expertise in ion channel therapeutics, particularly its lead program for the treatment of Lambert-Eaton myasthenic syndrome (LEMS), aligns with Novartis’s strategic priorities. LEMS is a rare autoimmune disorder that causes muscle weakness.
According to Novartis’s Q3 2023 financial results, the company is focused on delivering innovative medicines and expanding its portfolio. This acquisition is a key component of that strategy.
Previous Reports
The possibility of a takeover offer from Novartis for avidity Biosciences was first reported by the Financial Times in August 2023. Financial Times reported that Novartis was considering a bid valuing Avidity at around $10 billion at that time, suggesting the final offer significantly exceeded initial expectations.
About the Companies
Novartis is a global healthcare company based in Basel, Switzerland. it provides innovative medicines, eye care, and generic pharmaceuticals to patients worldwide. Learn more about novartis.
Avidity Biosciences, headquartered in La Jolla, California, is a biotechnology company focused on the discovery and development of innovative therapies